Hospitalisation associated with use of the synthetic cannabinoid K2

New Zealand Medical Journal

Volumn 126, Issue 1377, 2013, Pages 18-22

  Glue, Paul ^a   Al Shaqsi, Sultan ^a   Hancock, Douglas ^b   Gale, Chris ^a   Strong, Brad ^c   Schep, Leo ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Wakari Hospital   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABINOID; NEUROLEPTIC AGENT; SYNTHETIC CANNABINOID K2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; MEDICAL AUDIT; MENTAL HOSPITAL; PARANOIA; PSYCHOSIS; RETROSPECTIVE STUDY; SUICIDAL BEHAVIOR; THOUGHT DISORDER;

ADOLESCENT; ADULT; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MENTAL DISORDERS; NEW ZEALAND; RETROSPECTIVE STUDIES; SELF REPORT; STREET DRUGS; TIME FACTORS; YOUNG ADULT;

EID: 84879936219     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Aung MM, Griffin G, Huffman JW, et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 2000;60:133-140.
2. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010;197:157-62.
3. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010;160:585-593.
4. Atwood BK, Lee D, Straiker A, et al. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 2011;659:139-145.
5. Gunderson EW, Haughey HM, Ait-Daoud N, et al. Spice and K2 herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012;21:320-6.
6. Müller H, Sperling W, Köhrmann M, et al. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophrenia Res 2010;118:309-310.
7. Vearrier D, Osterhoudt KC. A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care 2010;26:462-465.
8. Rodgman C, Kinzie E, Leimbach E. Bad Mojo: use of the new marijuana substitute leads to more and more ED visits for acute psychosis. Am J Emerg Med 2011;29:232.
9. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011;117:152-7.
10. Auwarter V, Dresen S, Weinmann W, et al. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009;44:832-7.
11. Thomas S, Bliss S, Malik M. Suicidal ideation and self-harm following K2 use. J Okla State Med Assoc 2012;105:430-3.
12. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011;168:1119.
13. Castellanos D, Singh S, Thornton G, et al. Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 2011;49:347-9
14. Chai YK, Wheeler Z, Herbison P, et al. Factors associated with hospitalization of adult psychiatric patients: cluster analysis. Australas Psychiatry 2013;21:141-6.
15. Tosato S, Lasalvia A, Bonetto C, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J Psychiatr Res 2013;47:438-44.